138
Participants
Start Date
March 31, 2008
Primary Completion Date
March 31, 2010
Study Completion Date
October 31, 2012
CP-751,871
Final dose 30 mg/kg IV on Day 1 of each 28 day cycle until either progression or toxicity
Pfizer Investigational Site, Parkville
Pfizer Investigational Site, Brisbane
Pfizer Investigational Site, New York
Pfizer Investigational Site, New York
Pfizer Investigational Site, Torino
Pfizer Investigational Site, Berlin
Pfizer Investigational Site, Milan
Pfizer Investigational Site, Madrid
Pfizer Investigational Site, Memphis
Pfizer Investigational Site, Bologna
Pfizer Investigational Site, Valencia
Pfizer Investigational Site, Münster
Pfizer Investigational Site, Petah Tikva
Pfizer Investigational Site, Rochester
Pfizer Investigational Site, Lille
Pfizer Investigational Site, Lyon
Pfizer Investigational Site, Paris
Pfizer Investigational Site, Dallas
Pfizer Investigational Site, Freiburg im Breisgau
Pfizer Investigational Site, München
Pfizer Investigational Site, Jerusalem
Pfizer Investigational Site, Villejuif
Pfizer Investigational Site, Seattle
Pfizer Investigational Site, Providencia
Pfizer Investigational Site, Tampa
Pfizer Investigational Site, Boston
Pfizer Investigational Site, Philadelphia
Pfizer Investigational Site, Providence
Pfizer Investigational Site, São Paulo
Pfizer Investigational Site, Toronto
Pfizer Investigational Site, Barcelona
Pfizer Investigational Site, Esplugues de Llobregat
Pfizer Investigational Site, Sutton
Pfizer Investigational Site, London
Pfizer Investigational Site, London
Pfizer Investigational Site, Oxford
Pfizer Investigational Site, Oxford
Lead Sponsor
Pfizer
INDUSTRY